Rocket Pharmaceuticals (RCKT)

• Market cap: $289M
• 1 day: -1.85%
• 5 days: -8.93%
• 1 month: -26.18%
• 3 months: -48.14%
• 6 months: -21.13%
• Year to date: -23.41%
• 1 year: -12.25%
• 5 years: -94.16%
• 10 years: -92.15%
• Sector: Healthcare
• Industry: Biotechnology

About: Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.

Employees: 202